Richard A Moravec

2.0k total citations · 1 hit paper
21 papers, 1.5k citations indexed

About

Richard A Moravec is a scholar working on Molecular Biology, Computational Theory and Mathematics and Biomedical Engineering. According to data from OpenAlex, Richard A Moravec has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Computational Theory and Mathematics and 5 papers in Biomedical Engineering. Recurrent topics in Richard A Moravec's work include Computational Drug Discovery Methods (5 papers), Cell death mechanisms and regulation (4 papers) and 3D Printing in Biomedical Research (4 papers). Richard A Moravec is often cited by papers focused on Computational Drug Discovery Methods (5 papers), Cell death mechanisms and regulation (4 papers) and 3D Printing in Biomedical Research (4 papers). Richard A Moravec collaborates with scholars based in United States and Czechia. Richard A Moravec's co-authors include Terry Riss, Andrew L. Niles, Sarah Duellman, Hélène A Benink, Tracy J Worzella, Lisa Minor, William J. Daily, Martha A. O’Brien, Robert F. Bulleit and Dieter H. Klaubert and has published in prestigious journals such as Analytical Biochemistry, Journal of Immunological Methods and Materials.

In The Last Decade

Richard A Moravec

21 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cell Viability Assays

2016 349 citations Terry Riss, Richard A Moravec et al. Europe PMC (PubMed Central) profile →

Peers

Countries citing papers authored by Richard A Moravec

Since Specialization

Citations

This map shows the geographic impact of Richard A Moravec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A Moravec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A Moravec more than expected).

Fields of papers citing papers by Richard A Moravec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A Moravec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A Moravec. The network helps show where Richard A Moravec may publish in the future.

Co-authorship network of co-authors of Richard A Moravec

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A Moravec. A scholar is included among the top collaborators of Richard A Moravec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A Moravec. Richard A Moravec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treating Cells as Reagents to Design Reproducible Assays 2021 ·SLAS DISCOVERY ·Terry Riss, Richard A Moravec, Sarah Duellman, Andrew L. Niles	8
2	Damage Analysis of Composite CFRP Tubes Using Acoustic Emission Monitoring and Pattern Recognition Approach 2021 ·Materials ·(unknown), (unknown), Martin Fusek, (unknown), Richard A Moravec	41
3	Cell Viability Assays breakdown → 2016 ·Europe PMC (PubMed Central) ·Terry Riss, Richard A Moravec, Andrew L. Niles, Sarah Duellman, Hélène A Benink, Tracy J Worzella, Lisa Minor	349
4	Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies 2014 ·Journal of Immunological Methods ·Zhi-jie Jey Cheng, (unknown), Aileen Paguio, Richard A Moravec, (unknown), Frank Fan, Teresa K. Surowy	63
5	Cytotoxicity Testing: Measuring Viable Cells, Dead Cells, and Detecting Mechanism of Cell Death 2011 ·Methods in molecular biology ·Terry Riss, Richard A Moravec, Andrew L. Niles	76
6	Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format 2009 ·Analytical Biochemistry ·Richard A Moravec, Martha A. O’Brien, William J. Daily, (unknown), Laurent Bernad, Terry Riss	54
7	In Vitro Viability and Cytotoxicity Testing and Same-Well Multi-Parametric Combinations for High Throughput Screening 2009 ·PubMed ·Andrew L. Niles, Richard A Moravec, Terry Riss	113
8	Update onin vitrocytotoxicity assays for drug development 2008 ·Expert Opinion on Drug Discovery ·Andrew L. Niles, Richard A Moravec, Terry Riss	104
9	Multiplex Caspase Activity and Cytotoxicity Assays 2008 ·Humana Press eBooks ·Andrew L. Niles, Richard A Moravec, Terry Riss	10
10	Caspase Activity Assays 2008 ·Humana Press eBooks ·Andrew L. Niles, Richard A Moravec, Terry Riss	24
11	Homogeneous, Bioluminescent Proteasome Assays 2008 ·Humana Press eBooks ·Martha A. O’Brien, Richard A Moravec, Terry Riss, Robert F. Bulleit	12
12	A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers 2007 ·Analytical Biochemistry ·Andrew L. Niles, Richard A Moravec, (unknown), (unknown), William J. Daily, Terry Riss	129
13	MULTITOX-FLUOR MULTIPLEX CYTOTOXICITY ASSAY TECHNOLOGY 2006 ·Andrew L. Niles, Richard A Moravec, (unknown), William J. Daily, Laurent Bernad, (unknown), Kay E. Rashka, Deborah E. de Lange, Terry Riss	6
14	Homogeneous, Bioluminescent Protease Assays: Caspase-3 as a Model 2005 ·SLAS DISCOVERY ·Martha A. O’Brien, William J. Daily, (unknown), Richard A Moravec, (unknown), Dieter H. Klaubert, Robert F. Bulleit, Keith V. Wood	103
15	Use of Multiple Assay Endpoints to Investigate the Effects of Incubation Time, Dose of Toxin, and Plating Density in Cell-Based Cytotoxicity Assays 2004 ·Assay and Drug Development Technologies ·Terry Riss, Richard A Moravec	268
16	Apoptosis Marker Assays for HTS 2004 ·Terry Riss, Martha A. O’Brien, Richard A Moravec, Kevin R. Kupcho, Andrew L. Niles	2
17	CASPASE-GLO™ 3/7 ASSAY: USE FEWER CELLS AND SPEND LESS TIME WITH THIS HOMOGENEOUS ASSAY 2003 ·Richard A Moravec, Terry Riss	4
18	CELLTITER-GLO™ LUMINESCENT CELL VIABILITY ASSAY: A SENSITIVE AND RAPID METHOD FOR DETERMINING CELL VIABILITY 2001 ·Rita R. Hannah, Michael Beck, Richard A Moravec, Terry Riss	32
19	Poly (ADP-Ribose) Polymerase Cleavage Monitored In Situ in Apoptotic Cells 2001 ·BioTechniques ·Martha A. O’Brien, Richard A Moravec, Terry Riss	51
20	The role of antioxidants in skin immune reactions: The use of flow cytometry to determine alterations in la-positive epidermal cells in allergic contact dermatitis 1989 ·Journal of the Society of Cosmetic Chemists ·Lawrence A. Rheins, Richard A Moravec, Michael L. Nordlund, Linda S. Trinkle, James J. Nordlund	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact